Literature DB >> 7578385

Rhabdomyosarcoma and other soft tissue sarcomas of childhood.

A S Pappo1.   

Abstract

This review of the past year's literature summarizes the most relevant advances in the biology and therapy of rhabdomyosarcoma and other pediatric soft tissue sarcomas. The results of the third Intergroup Rhabdomyosarcoma Study clearly show that therapy based on specific risk factors offers the best chance of cure for children with rhabdomyosarcoma. The recent identification of nonrandom chromosomal translocations within distinct histologic subtypes of rhabdomyosarcoma and nonrhabdomyosarcoma soft tissue sarcomas offers a unique opportunity to improve our ability to diagnose, stage, and monitor these patients. Finally, identification of the genetic features that characterize these tumors will help us better understand the mechanisms involved in tumorigenesis and will facilitate the development of novel specific therapies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578385     DOI: 10.1097/00001622-199507000-00012

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  10 in total

1.  Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.

Authors:  Erin R Rudzinski; James R Anderson; Elizabeth R Lyden; Julia A Bridge; Frederic G Barr; Julie M Gastier-Foster; Karen Bachmeyer; Stephen X Skapek; Douglas S Hawkins; Lisa A Teot; David M Parham
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

2.  Congenital embryonal rhabdomyosarcoma caused by heterozygous concomitant PTCH1 and PTCH2 germline mutations.

Authors:  Julia Taeubner; Triantafyllia Brozou; Nan Qin; Jasmin Bartl; Sebastian Ginzel; Joerg Schaper; Joerg Felsberg; Simone Fulda; Christian Vokuhl; Arndt Borkhardt; Michaela Kuhlen
Journal:  Eur J Hum Genet       Date:  2017-12-11       Impact factor: 4.246

Review 3.  Molecular diagnostics in the management of rhabdomyosarcoma.

Authors:  Michael A Arnold; Fredric G Barr
Journal:  Expert Rev Mol Diagn       Date:  2017-01-06       Impact factor: 5.225

4.  An antenatally diagnosed rhabdomyosarcoma of the bladder treated without extensive surgery.

Authors:  Shadi Abdar Esfahani; Laleh Montaser-Kouhsari; Parisa Saeedi; Zhina Sadeghi; Abdol-Mohammad Kajbafzadeh
Journal:  Nat Rev Urol       Date:  2009-08       Impact factor: 14.432

5.  Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis.

Authors:  M Rajurkar; H Huang; J L Cotton; J K Brooks; J Sicklick; A P McMahon; J Mao
Journal:  Oncogene       Date:  2013-11-25       Impact factor: 9.867

6.  Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression.

Authors:  F A Scholl; D R Betts; F K Niggli; B W Schäfer
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

7.  The Expression of c-Myb Correlates with the Levels of Rhabdomyosarcoma-specific Marker Myogenin.

Authors:  Petr Kaspar; Martina Zikova; Petr Bartunek; Jaroslav Sterba; Hynek Strnad; Leos Kren; Radislav Sedlacek
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

8.  Rhabdomyosarcoma of the maxillary gingiva.

Authors:  Mina Motallebnejad; Pouyan Aminishakib; Samira Derakhshan; Abbas Karimi
Journal:  Dent Res J (Isfahan)       Date:  2018 Jan-Feb

9.  Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.

Authors:  J Prados; C Melguizo; J A Marchal; C Vélez; L Alvarez; A Aránega
Journal:  Jpn J Cancer Res       Date:  1999-07

10.  The PAX3-FOXO1 oncogene alters exosome miRNA content and leads to paracrine effects mediated by exosomal miR-486.

Authors:  Farah Ghamloush; Sandra E Ghayad; Ghina Rammal; Assil Fahs; Abeer J Ayoub; Zeina Merabi; Mohamad Harajly; Hassan Zalzali; Raya Saab
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.